Fresenius SE & Co. KGaA : A trend reversal is in sight
Entry price | Target | Stop-loss | Potential |
---|
€46.2 |
€51.36 |
€42.94 |
+11.17% |
---|
Fresenius reflects attractive technical aspects that could allow investors to expect a trend reversal over the medium term.
Strengths● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
● The group shows a rather high level of debt in proportion to its EBITDA.
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
● Revenue estimates are regularly revised downwards for the current and coming years.
● For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
● For the last four months, EPS estimates made by Thomson-Reuters analysts have been revised downwards.
● The underlying tendency is negative on the weekly chart below the resistance at 53.02 EUR
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.